Cargando…
Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples
Rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate directed against Delta-like protein 3 (DLL3), is under development for patients with small cell lung cancer (SCLC). DLL3 is expressed on the majority of SCLC samples. Because SCLC is rarely biopsied in the course of disease, data regarding...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531433/ https://www.ncbi.nlm.nih.gov/pubmed/34692726 http://dx.doi.org/10.3389/fmed.2021.734901 |
_version_ | 1784586856973729792 |
---|---|
author | Kuempers, Christiane Jagomast, Tobias Krupar, Rosemarie Paulsen, Finn-Ole Heidel, Carsten Ribbat-Idel, Julika Idel, Christian Märkl, Bruno Anlauf, Martin Berezowska, Sabina Tiemann, Markus Bösmüller, Hans Fend, Falko Kalsdorf, Barbara Bohnet, Sabine Dreyer, Eva Sailer, Verena Kirfel, Jutta Perner, Sven |
author_facet | Kuempers, Christiane Jagomast, Tobias Krupar, Rosemarie Paulsen, Finn-Ole Heidel, Carsten Ribbat-Idel, Julika Idel, Christian Märkl, Bruno Anlauf, Martin Berezowska, Sabina Tiemann, Markus Bösmüller, Hans Fend, Falko Kalsdorf, Barbara Bohnet, Sabine Dreyer, Eva Sailer, Verena Kirfel, Jutta Perner, Sven |
author_sort | Kuempers, Christiane |
collection | PubMed |
description | Rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate directed against Delta-like protein 3 (DLL3), is under development for patients with small cell lung cancer (SCLC). DLL3 is expressed on the majority of SCLC samples. Because SCLC is rarely biopsied in the course of disease, data regarding DLL3 expression in relapses is not available. The aim of this study was to investigate the expression of DLL3 in chemorelapsed (but untreated with Rova-T) SCLC samples and compare the results with chemonaive counterparts. Two evaluation methods to assess DLL3 expression were explored. Additionally, we assessed if DLL3 expression of chemorelapsed and/or chemonaive samples has prognostic impact and if it correlates with other clinicopathological data. The study included 30 paired SCLC samples, which were stained with an anti DLL3 antibody. DLL3 expression was assessed using tumor proportion score (TPS) and H-score and was categorized as DLL3 low (TPS < 50%, H-score ≤ 150) and DLL3 high (TPS ≥ 50%, H-score > 150). Expression data were correlated with clinicopathological characteristics. Kaplan–Meier curves were used to illustrate overall survival (OS) depending on DLL3 expression in chemonaive and chemorelapsed samples, respectively, and depending on dynamics of expression during course of therapy. DLL3 was expressed in 86.6% chemonaive and 80% chemorelapsed SCLC samples without significant differences between the two groups. However, the extent of expression varied in a substantial proportion of pairs (36.6% with TPS, 43.3% with H-score), defined as a shift from low to high or high to low expression. TPS and H-score provided comparable results. There were no profound correlations with clinicopathological data. Survival analysis revealed a trend toward a more favorable OS in DLL low-expressing chemonaive SCLC (p = 0.57) and, in turn, in DLL3 high-expressing chemorelapsed SCLC (p = 0.42) as well as in SCLC demonstrating a shift from low to high expression (p = 0.56) without being statistically significant. This is the first study to investigate DLL3 expression in a large cohort of rare paired chemonaive-chemorelapsed SCLC specimens. Comparative analysis revealed that DLL3 expression was not stable during the course of therapy, suggesting therapy-based alterations. Unlike in chemonaive samples, a high DLL3 expression in chemorelapsed samples indicated a trend for a more favorable prognosis. Our results highlight the importance to investigate DLL3 in latest chemorelapsed SCLC tumor tissue. |
format | Online Article Text |
id | pubmed-8531433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85314332021-10-23 Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples Kuempers, Christiane Jagomast, Tobias Krupar, Rosemarie Paulsen, Finn-Ole Heidel, Carsten Ribbat-Idel, Julika Idel, Christian Märkl, Bruno Anlauf, Martin Berezowska, Sabina Tiemann, Markus Bösmüller, Hans Fend, Falko Kalsdorf, Barbara Bohnet, Sabine Dreyer, Eva Sailer, Verena Kirfel, Jutta Perner, Sven Front Med (Lausanne) Medicine Rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate directed against Delta-like protein 3 (DLL3), is under development for patients with small cell lung cancer (SCLC). DLL3 is expressed on the majority of SCLC samples. Because SCLC is rarely biopsied in the course of disease, data regarding DLL3 expression in relapses is not available. The aim of this study was to investigate the expression of DLL3 in chemorelapsed (but untreated with Rova-T) SCLC samples and compare the results with chemonaive counterparts. Two evaluation methods to assess DLL3 expression were explored. Additionally, we assessed if DLL3 expression of chemorelapsed and/or chemonaive samples has prognostic impact and if it correlates with other clinicopathological data. The study included 30 paired SCLC samples, which were stained with an anti DLL3 antibody. DLL3 expression was assessed using tumor proportion score (TPS) and H-score and was categorized as DLL3 low (TPS < 50%, H-score ≤ 150) and DLL3 high (TPS ≥ 50%, H-score > 150). Expression data were correlated with clinicopathological characteristics. Kaplan–Meier curves were used to illustrate overall survival (OS) depending on DLL3 expression in chemonaive and chemorelapsed samples, respectively, and depending on dynamics of expression during course of therapy. DLL3 was expressed in 86.6% chemonaive and 80% chemorelapsed SCLC samples without significant differences between the two groups. However, the extent of expression varied in a substantial proportion of pairs (36.6% with TPS, 43.3% with H-score), defined as a shift from low to high or high to low expression. TPS and H-score provided comparable results. There were no profound correlations with clinicopathological data. Survival analysis revealed a trend toward a more favorable OS in DLL low-expressing chemonaive SCLC (p = 0.57) and, in turn, in DLL3 high-expressing chemorelapsed SCLC (p = 0.42) as well as in SCLC demonstrating a shift from low to high expression (p = 0.56) without being statistically significant. This is the first study to investigate DLL3 expression in a large cohort of rare paired chemonaive-chemorelapsed SCLC specimens. Comparative analysis revealed that DLL3 expression was not stable during the course of therapy, suggesting therapy-based alterations. Unlike in chemonaive samples, a high DLL3 expression in chemorelapsed samples indicated a trend for a more favorable prognosis. Our results highlight the importance to investigate DLL3 in latest chemorelapsed SCLC tumor tissue. Frontiers Media S.A. 2021-10-08 /pmc/articles/PMC8531433/ /pubmed/34692726 http://dx.doi.org/10.3389/fmed.2021.734901 Text en Copyright © 2021 Kuempers, Jagomast, Krupar, Paulsen, Heidel, Ribbat-Idel, Idel, Märkl, Anlauf, Berezowska, Tiemann, Bösmüller, Fend, Kalsdorf, Bohnet, Dreyer, Sailer, Kirfel and Perner. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Kuempers, Christiane Jagomast, Tobias Krupar, Rosemarie Paulsen, Finn-Ole Heidel, Carsten Ribbat-Idel, Julika Idel, Christian Märkl, Bruno Anlauf, Martin Berezowska, Sabina Tiemann, Markus Bösmüller, Hans Fend, Falko Kalsdorf, Barbara Bohnet, Sabine Dreyer, Eva Sailer, Verena Kirfel, Jutta Perner, Sven Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples |
title | Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples |
title_full | Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples |
title_fullStr | Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples |
title_full_unstemmed | Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples |
title_short | Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples |
title_sort | delta-like protein 3 expression in paired chemonaive and chemorelapsed small cell lung cancer samples |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531433/ https://www.ncbi.nlm.nih.gov/pubmed/34692726 http://dx.doi.org/10.3389/fmed.2021.734901 |
work_keys_str_mv | AT kuemperschristiane deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT jagomasttobias deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT kruparrosemarie deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT paulsenfinnole deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT heidelcarsten deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT ribbatideljulika deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT idelchristian deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT marklbruno deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT anlaufmartin deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT berezowskasabina deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT tiemannmarkus deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT bosmullerhans deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT fendfalko deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT kalsdorfbarbara deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT bohnetsabine deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT dreyereva deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT sailerverena deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT kirfeljutta deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples AT pernersven deltalikeprotein3expressioninpairedchemonaiveandchemorelapsedsmallcelllungcancersamples |